AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound that binds to leukocytes, wherein said compound is represented by the formula (1):

Z-Y-Leu-Phe-$(X)_n$-Lys($\underline{NH_2}$~~NH2~~)$_m$-ε(-R-$(T)_{\underline{1}}$~~1~~-U) (1)

~~(~~wherein, in the formula (1),

Z represents a protecting group for an amino group;

Y represents Met or Nle;~~ in $(X)_n$,~~

X represents a spacer consisting of one or more of amino acids and/or synthetic organic compounds;~~, and~~

n represents 1 or 0;~~ in $(NH_2)_m$,~~

NH_2 represents an amide group as a protecting group for a carboxyl group in the α position of Lys;~~, and~~

m represents 1 or 0; ~~in ε(- R -$(T)_l$- U),~~

R represents Ser or Thr binding to an ε–amino group of Lys through an amide bond;~~,~~

T represents a spacer consisting of one or more of amino acids and/or synthetic organic compounds;~~,~~

l represents 1 or 0;~~,~~ and

U represents a group which can be labeled with a metal;

with the proviso that said X and T may be the same or different from each other).

2. (previously presented): The compound according to claim 1, wherein U in the formula (1) is a group consisting of a peptide represented by –Cys-A1-A2 (A1 and A2 are each an amino acid except for Cys and Pro), nitrogen-containing cyclic compounds with 8 to 20 carbon atoms, nitrogen-containing cyclic carboxylic acid compounds with 8 to 20 carbon atoms, derivatives of nitrogen-containing cyclic carboxylic acid compounds with 8 to 20 carbon atoms or alkylenamine carboxylic acids with 4 to 10 carbon atoms, which can be labeled with a metal.

3. (canceled).

4. (previously presented): The compound according to claim 1, wherein said compound represented by the formula (1) is one selected from the group consisting of:

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-Cys-Gly-Asn);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-Cys-Asp-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-Cys-Gly-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid);

formyl-Nle-Leu-Phe-Lys(NH_2)-ε-(-Ser-D-Ser-Asn-D-Arg-Cys- Asp-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-diethylenetriamine pentaacetic acid);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-1,4,8,11-tetraazacyclotetradecane-butyric acid);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-1,4,8,11-tetraazacyclotetradecane-butyric acid);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Ser-Asn-1,4,8,11-tetraazacyclotetradecane-butyric acid);

acetyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp);

carbamyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp); and

methyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp).

5. (currently amended): A composition comprising a complex formed between a compound of formula (1) and a metal ion or a metal oxide of ~~The compound according to claim 1 labeled with~~ a radioactive metal or a paramagnetic metal, and a pharmaceutically acceptable carrier: wherein the compound is represented by the formula (1):

$Z\text{-}Y\text{-}Leu\text{-}Phe\text{-}(X)_n\text{-}Lys(NH_2)_m\text{-}\varepsilon(\text{-}R\text{-}(T)_1\text{-}U)$ (1)

wherein, in the formula (1),

Z represents a protecting group for an amino group;

Y represents Met or Nle;

X represents a spacer consisting of one or more of amino acids and/or synthetic organic compounds;

n represents 1 or 0;

NH_2 represents an amide group as a protecting group for a carboxyl group in the α position of Lys;

m represents 1 or 0;

R represents Ser or Thr binding to an ε–amino group of Lys through an amide bond;

T represents a spacer consisting of one or more of amino acids and/or synthetic organic compounds;

l represents 1 or 0; and U represents a group which can be labeled with a metal;

with the proviso that said X and T may be the same or different from each other.

6. (currently amended): The composition~~compound~~ according to claim 5, wherein said radioactive metal is Tc-99m, In-111, Ga-67, Cu~~CU~~-64 or Ga-68.

7. (currently amended): A method for imaging a site of vigorous leukocyte infiltration accompanied by immune reaction in an individual, said method comprising administering to an individual an effective amount of the composition~~compound~~ according to claim 6 and conducting SPECT (single photon emission computed technology) or PET (positron emission tomography) imaging on the individual.

8-9. (canceled).

10. (currently amended): The composition~~compound~~ according to claim 5, wherein said paramagnetic metal is Gd, Fe, Mn or Cu.

11. (currently amended): A method for imaging a site of vigorous leukocyte infiltration accompanied by immune reaction in an individual, said method comprising administering to said individual an effective amount of the composition~~compound~~ according to claim 10 and conducting MRI (magnetic resonance imaging) on the individual.

12. (currently amended): The composition~~compound~~ according to claim 5, wherein said radioactive metal is Y-90, Sn-117m, Sm-153, Re-186 or Re-188.

13. (currently amended): A method of radiotherapy, comprising administering to a patient in need of therapy an effective amount of the composition~~compound~~ according to claim 12.

14. (previously presented): The compound according to claim 2, wherein said compound represented by the formula (1) is one selected from the group consisting of:

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-Cys-Gly-Asn);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-Cys-Asp-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-Cys-Gly-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid);

formyl-Nle-Leu-Phe-Lys(NH_2)-ε-(-Ser-D-Ser-Asn-D-Arg-Cys- Asp-Asp);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-diethylenetriamine pentaacetic acid);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-1,4,8,11-tetraazacyclotetradecane-butyric acid);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-1,4,8,11-tetraazacyclotetradecane-butyric acid);

formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Ser-Asn-1,4,8,11-tetraazacyclotetradecane-butyric acid);

acetyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp);

carbamyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp); and

methyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH_2)-ε-(-Ser-D-Arg-Asp-Cys-Asp-Asp).

15. (previously presented): A composition comprising the compound of any one of claims 5, 6, 10, or 12, and a pharmaceutically acceptable carrier.